No profile data available.
PMV Pharmaceuticals, Inc. (PMVP) is a healthcare company in the additional cancer treatment drugs industry, based in Princeton, United States, with about 54 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$77.74 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $114.78 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
PMV Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$114.78 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Foghorn Therapeutics Inc. (FHTX), enGene Holdings Inc. (ENGN), Genelux Corporation (GNLX), Black Diamond Therapeutics, Inc. (BDTX).